Eli Lilly and Company, an American pharmaceutical company, completed the acquisition of Versanis, a private clinical-stage biopharmaceutical company, for $1.9bn. "Combining our current incretin portfolio, including tirzepatide, with activin receptor blockers such as bimagrumab, could be the next major step in innovative treatments for those living with cardiometabolic diseases, like obesity. The wealth of knowledge that our new colleagues from Versanis will bring to Lilly will propel our research and development efforts forward, ultimately benefiting patients around the world," Ruth Gimeno, Eli Lilly Vice President.